Discriminant function: Difference between revisions
No edit summary |
No edit summary |
||
Line 20: | Line 20: | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Medical scoring system]] | [[Category:Medical scoring system]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 13:47, 6 May 2009
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Discriminant function (also called modified Maddrey's discriminant function) was originally described by Maddrey and Boitnott[1] to predict prognosis in alcoholic hepatitis. It is calculated by a simple formula:
<math>\left [{4}.{6}\times\ prothombin\ time\ -\ control\ value\ (seconds)\right ]\ +\ serum\ bilirubin\ (mg/dl)\,</math>
Prospective studies have shown that, it is useful in predicting short term prognosis especially mortality within 30 days[2]. A value more than 32 implies poor outcome with one month mortality ranging between 35% to 45%[3].
See also
Reference list
- ↑ Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI (1978). "Corticosteroid therapy of alcoholic hepatitis". Gastroenterology. 75 (2): 193–9. PMID 352788.
- ↑ Sheth M, Riggs M, Patel T (2002). "Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis". BMC gastroenterology. 2: 2. PMID 11835693.
- ↑ Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000). "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial". Gastroenterology. 119 (6): 1637–48. PMID 11113085.